Recombinant Erythropoietin Market, By Drug Type (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application (Cancer, Hematology, Renal diseases, Neurology, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmac
Recombinant Erythropoietin Market, By Drug Type (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application (Cancer, Hematology, Renal diseases, Neurology, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)
Recombinant erythropoietin is a bioengineered version of a naturally occurring hormone, erythropoietin, which is produced by the kidneys to stimulate the production of red blood cells. This recombinant version is produced in a laboratory, typically using genetically modified bacteria or mammalian cells. Recombinant erythropoietin is used primarily to treat anemia, particularly in individuals with chronic kidney disease or undergoing chemotherapy for cancer. It works by stimulating the bone marrow to produce more red blood cells, thereby increasing the oxygen-carrying capacity of the blood.
Recombinant erythropoietin (rEPO) is a revolutionary medical development that has transformed the treatment of anemia and related conditions. Erythropoietin is a hormone naturally produced by the kidneys, stimulating the production of red blood cells (RBC) in the bone marrow. Recombinant DNA technology has made it possible to produce synthetic erythropoietin in the laboratory, resulting in the creation of rEPO. This has provided has provided a highly effective approach to managing anemia, particularly in patients with chronic kidney diseases, cancer, and certain genetic disorders. By administering rEPO, healthcare professionals can stimulate RBC production, improve oxygen-carrying capacity, and alleviating symptoms of anemia, such as fatigue and weakness. Furthermore, rEPO has demonstrated significant benefits in reducing the need for blood transfusions and enhancing quality of life for patients. The widespread adoption of recombinant erythropoietin has revolutionized anemia management and continues to play a crucial role in various medical fields.
Market Dynamics:
The rising prevalence of chronic diseases such as chronic kidney disease (ckd) and cancer is anticipated to drive growth of the global recombinant erythropoietin market over the forecast period. For instance, according to data published on January 12, 2023, by John Wiley & Sons, Inc., a publishing company, in 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the U.S.
However, stringent regulatory requirements, safety concerns, side effects, and reimbursement challenges are expected to hamper growth of the global recombinant erythropoietin market over the forecast period.
Key features of the study:
This report provides in-depth analysis of the global recombinant erythropoietin market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global recombinant erythropoietin market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Biocon Limited, LG Chem Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., Celltrion Inc., 3SBio Inc., BioSidus SA, Astellas Pharma Inc, and Lotus Pharmaceutical Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global recombinant erythropoietin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global recombinant erythropoietin market
Detailed Segmentation:
By Drug Type:
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
By Application:
Cancer
Hematology
Renal diseases
Neurology
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
Company Profiles:
Amgen Inc.
Johnson & Johnson (Janssen Pharmaceuticals)
Pfizer Inc.
F. Hoffmann-La Roche AG
Novartis AG
Biocon Limited
LG Chem Ltd.
Intas Pharmaceuticals Ltd.
Dr. Reddy's Laboratories Ltd.
Celltrion Inc.
3SBio Inc.
BioSidus SA
Astellas Pharma Inc
Lotus Pharmaceutical Co., Ltd
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Recombinant Erythropoietin, By Drug Type
Market Recombinant Erythropoietin, By Application
Market Recombinant Erythropoietin, By Distribution Channel
Market Recombinant Erythropoietin, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Rising prevalence of chronic kidney disease (ckd)
Restraints
Stringent Regulatory Requirements
Opportunities
Emerging Markets
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
4. Recombinant Erythropoietin Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Recombinant Erythropoietin Market , By Drug Type, 2018-2030, (US$ billion)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2019–2030
Segment Trends
Epoetin-alfa
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Epoetin-beta
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Darbepoetin-alfa
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
6. Recombinant Erythropoietin Market, By Application, 2018-2030, (US$ billion)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2019–2030
Segment Trends
Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Hematology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Renal diseases
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Neurology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
7. Recombinant Erythropoietin Market , By Distribution Channel, 2018-2030, (US$ billion)
Introduction
Market Share Analysis, 2023 and 2030 (%)
Y-o-Y Growth Analysis, 2019–2030
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ billion)
8. Recombinant Erythropoietin Market , By Region, 2018-2030, (US$ billion)
Introduction
Market Share Analysis, By Country, 2023 and 2030 (%)
Y-o-Y Growth Analysis, For Country 2019–2030
Country Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
U.S.
Canada
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
2018 - 2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018-2030,(US$ billion)
Market Size and Forecast, and Y-o-Y Growth, By Application , 2018-2030,(US$ billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,(US$ billion)
Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 - 2030, (US$ Bn)
North Africa
Central Africa
South Africa
9. Competitive Landscape
Amgen Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Johnson & Johnson (Janssen Pharmaceuticals)
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Pfizer Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
F. Hoffmann-La Roche AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Novartis AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Biocon Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
LG Chem Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Intas Pharmaceuticals Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Dr. Reddy's Laboratories Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Celltrion Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
3SBio Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
BioSidus SA
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Astellas Pharma Inc
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Lotus Pharmaceutical Co., Ltd
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views
10. Section
Research Methodology
About us
*Browse 35 market data tables and 34 figures on "Global Recombinant Erythropoietin Market” - Global forecast to 2030